Novan Stock Price, News & Analysis (NASDAQ:NOVN)

$3.30 -0.08 (-2.37 %)
(As of 02/22/2018 10:07 AM ET)
Previous Close$3.38
Today's Range$3.28 - $3.38
52-Week Range$2.82 - $8.19
Volume36,400 shs
Average Volume134,014 shs
Market Capitalization$87.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75

About Novan (NASDAQ:NOVN)

Novan logoNovan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080

Debt

Debt-to-Equity RatioN/A
Current Ratio1.37%
Quick Ratio1.37%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.95 per share
Price / Book1.69

Profitability

Trailing EPS($7.93)
Net Income$-59,690,000.00
Net MarginsN/A
Return on Equity-244.41%
Return on Assets-100.23%

Miscellaneous

Employees62
Outstanding Shares25,990,000

Novan (NASDAQ:NOVN) Frequently Asked Questions

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) announced its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.24. The business earned $0.10 million during the quarter, compared to the consensus estimate of $10.80 million. View Novan's Earnings History.

When will Novan make its next earnings announcement?

Novan is scheduled to release their next quarterly earnings announcement on Monday, March, 19th 2018. View Earnings Estimates for Novan.

Where is Novan's stock going? Where will Novan's stock price be in 2018?

2 brokerages have issued 12 month price objectives for Novan's shares. Their forecasts range from $6.00 to $11.00. On average, they expect Novan's share price to reach $8.50 in the next year. View Analyst Ratings for Novan.

Who are some of Novan's key competitors?

Who are Novan's key executives?

Novan's management team includes the folowing people:

  • Robert A. Ingram, Independent Chairman of the Board (Age 74)
  • Nathan Stasko Ph.D., President, Chief Scientific Officer, Director (Age 36)
  • G. Kelly Martin, Interim Chief Executive Officer, Director (Age 57)
  • Jeff N. Hunter, Chief Business Officer, Interim Chief Financial Officer and Principal Financial and Accounting Officer (Age 59)
  • Stanley Hollenbach J.D., Senior Vice President - Research and Development
  • Paula Brown Stafford, Chief Development Officer, Director
  • Brian M Johnson, Chief Commercial Officer (Age 50)
  • Machelle Sanders, Director
  • W. Kent Geer, Independent Director (Age 62)
  • Robert J Keegan, Independent Director (Age 69)

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Novan stock?

Novan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.25%). Company insiders that own Novan stock include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Who sold Novan stock? Who is selling Novan stock?

Novan's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Novan.

How do I buy Novan stock?

Shares of Novan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of Novan stock can currently be purchased for approximately $3.30.

How big of a company is Novan?

Novan has a market capitalization of $87.84 million. The company earns $-59,690,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Novan employs 62 workers across the globe.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]


MarketBeat Community Rating for Novan (NOVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novan (NASDAQ:NOVN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.50$8.50$8.50$17.24
Price Target Upside: 57.41% upside57.41% upside57.41% upside279.79% upside

Novan (NASDAQ:NOVN) Consensus Price Target History

Price Target History for Novan (NASDAQ:NOVN)

Novan (NASDAQ:NOVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017WedbushReiterated RatingNeutral$6.00HighView Rating Details
8/3/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
10/17/2016Credit Suisse GroupInitiated CoverageOutperform$27.00 -> $18.97N/AView Rating Details
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Novan (NASDAQ:NOVN) Earnings History and Estimates Chart

Earnings by Quarter for Novan (NASDAQ:NOVN)

Novan (NASDAQ NOVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/19/2018        
8/11/2017Q2 2017($0.71)($0.62)$0.60 million$0.67 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.49)($0.73)$10.80 million$0.10 millionViewN/AView Earnings Details
3/20/2017Q4 16($1.14)($0.82)ViewN/AView Earnings Details
11/14/2016Q3 16($1.40)($5.76)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novan (NASDAQ:NOVN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.43)($0.43)($0.43)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Novan (NASDAQ:NOVN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Novan (NASDAQ NOVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.72%
Institutional Ownership Percentage: 3.51%
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Institutional Ownership by Quarter for Novan (NASDAQ:NOVN)

Novan (NASDAQ NOVN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2017Robert Alexander IngramDirectorBuy12,000$4.57$54,840.0061,312View SEC Filing  
8/23/2017John W PalmourDirectorBuy12,000$3.99$47,880.00253,568View SEC Filing  
9/26/2016Life Sciences Holdings L MalinMajor ShareholderBuy800,000$11.00$8,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novan (NASDAQ NOVN) News Headlines

Source:
DateHeadline
Treatment with Novartis Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflationTreatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
finance.yahoo.com - February 22 at 9:28 AM
Dr. Eugene Sun Appointed to Novan Board of DirectorsDr. Eugene Sun Appointed to Novan Board of Directors
finance.yahoo.com - February 21 at 9:52 AM
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasisNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
finance.yahoo.com - February 16 at 4:26 PM
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasisNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
finance.yahoo.com - February 16 at 4:26 PM
Novan Inc (NOVN) Expected to Post Earnings of -$0.55 Per ShareNovan Inc (NOVN) Expected to Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - February 15 at 5:08 PM
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasisNovartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
finance.yahoo.com - February 8 at 9:03 AM
SAS founder Goodnights investment firm becomes Novans largest stockholderSAS founder Goodnight's investment firm becomes Novan's largest stockholder
finance.yahoo.com - January 30 at 4:37 PM
2 Novan execs out as company pushes to broaden focus2 Novan execs out as company pushes to broaden focus
finance.yahoo.com - January 25 at 4:34 PM
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
finance.yahoo.com - January 25 at 4:34 PM
Trading GE after earnings. Plus, the trade on Kroger & No...Trading GE after earnings. Plus, the trade on Kroger & No...
finance.yahoo.com - January 24 at 4:55 PM
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
finance.yahoo.com - January 24 at 4:55 PM
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision lossNovartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
finance.yahoo.com - January 24 at 4:55 PM
Novan (NOVN) Prices 10M Share Common Offering at $4.66/ShNovan (NOVN) Prices 10M Share Common Offering at $4.66/Sh
www.streetinsider.com - January 6 at 9:33 AM
Novan looks to raise $38M in public offeringNovan looks to raise $38M in public offering
finance.yahoo.com - January 5 at 5:04 PM
Novan (NOVN) Plans Common Stock OfferingNovan (NOVN) Plans Common Stock Offering
www.streetinsider.com - January 5 at 9:37 AM
Novan Announces Proposed Public Offering of Common Stock and WarrantsNovan Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - January 4 at 5:19 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - January 2 at 6:40 PM
Novan (NOVN) Stock Rating Upgraded by ValuEngineNovan (NOVN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - January 1 at 3:10 PM
NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit ...NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit ...
www.businesswire.com - December 31 at 9:20 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline – NOVNSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline – NOVN
finance.yahoo.com - December 23 at 7:37 PM
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its labelNovartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
finance.yahoo.com - December 22 at 9:17 PM
Glancy Prongay & Murray LLP Announces the...Glancy Prongay & Murray LLP Announces the...
www.benzinga.com - December 21 at 9:31 AM
NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 18 at 5:18 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - December 18 at 5:18 PM
NOVN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Novan, Inc. InvestorsNOVN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Novan, Inc. Investors
finance.yahoo.com - December 18 at 5:18 PM
Lawsuit for investors in NASDAQ:NOVN shares against Novan Inc announced by Shareholders FoundationLawsuit for investors in NASDAQ:NOVN shares against Novan Inc announced by Shareholders Foundation
finance.yahoo.com - December 18 at 9:50 AM
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2
finance.yahoo.com - December 14 at 5:50 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVNEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN
finance.yahoo.com - December 14 at 9:39 AM
CORRECTING and REPLACING Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class ActionCORRECTING and REPLACING Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 11 at 5:29 PM
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancerPrimary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
finance.yahoo.com - December 10 at 5:30 PM
Stocks tread lower, Bitcoin surges to record highStocks tread lower, Bitcoin surges to record high
finance.yahoo.com - December 8 at 9:32 AM
The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)
finance.yahoo.com - December 7 at 5:43 PM
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
finance.yahoo.com - December 6 at 5:18 PM
Stocks start in the green despite major tax bill concernsStocks start in the green despite major tax bill concerns
finance.yahoo.com - December 6 at 9:41 AM
IMPORTANT NOVAN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina against Novan, Inc.IMPORTANT NOVAN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina against Novan, Inc.
finance.yahoo.com - December 5 at 5:14 PM
Novan (NOVN) Reports First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414Novan (NOVN) Reports First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
www.streetinsider.com - December 5 at 10:14 AM
NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 4 at 5:16 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline: January 2, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline: January 2, 2018
finance.yahoo.com - December 4 at 5:16 PM
Novan (NOVN) Upgraded at ValuEngineNovan (NOVN) Upgraded at ValuEngine
www.americanbankingnews.com - December 2 at 11:58 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVNSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVN
finance.yahoo.com - December 2 at 5:08 PM
NOVAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS...NOVAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS...
www.benzinga.com - December 2 at 9:47 AM
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine preventionNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
finance.yahoo.com - November 29 at 5:36 PM
NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 28 at 5:18 PM
Novartis Ultibro® Breezhaler® significantly improved COPD patients lung function after direct switch from Seretide®Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
finance.yahoo.com - November 27 at 4:45 PM
EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 27 at 4:45 PM
NOVAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class ...NOVAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class ...
www.businesswire.com - November 26 at 9:23 AM
Cohen Milstein Sellers & Toll PLLC Announces Investigation of Novan Inc.Cohen Milstein Sellers & Toll PLLC Announces Investigation of Novan Inc.
finance.yahoo.com - November 18 at 8:38 AM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Novan, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Novan, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - November 18 at 8:38 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novan, Inc. (NOVN) & Lead Plaintiff Deadline - January 2, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novan, Inc. (NOVN) & Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - November 18 at 8:37 AM
NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 18 at 8:37 AM

SEC Filings

Novan (NASDAQ:NOVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novan (NASDAQ:NOVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novan (NASDAQ NOVN) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.